About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sigyn Therapeutics Appoints Dr. Christoph Zaba to Its Scientific Advisory Board

By: NewMediaWire

SAN DIEGO, CA. - September 11, 2025 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a developer of dialysis-like therapies to address cardiovascular disease and cancer, today announced the appointment of Dr. Christoph Zaba to its Scientific Advisory Board. 

Dr. Zaba is an innovation and business development leader with extensive experience in medical technology, extracorporeal therapies, and international product management. During his tenure at Fresenius Medical Care, he directed global product management in the field of therapeutic apheresis, advancing treatments in nephrology, dermatology, neurology, and cardiovascular medicine. His work included immunoadsorption therapies for autoimmune diseases and lipoprotein apheresis for the removal of pathogenic lipoproteins from the blood.

Lipoprotein apheresis (LA) is an extracorporeal treatment methodology to reduce the presence of lipoprotein(a) [Lp(a)] and low-density lipoprotein cholesterol [LDL-C] in the bloodstream.  In the treatment of cardiovascular disease (leading cause of global deaths), studies of lipoprotein apheresis have reported 55% to 98% reductions in major adverse cardiovascular events (MACE).

Sigyn Therapy™ is a whole blood adsorption technology being advanced to reduce the bloodstream presence of both Lp(a) and LDL-C while simultaneously targeting inflammatory molecules that fuel cardiovascular disease progression. On September 3rd, the Company disclosed plans to commence a multi-site clinical feasibility study of Sigyn Therapy™ in high-risk cardiovascular disease (CVD) subjects with end-stage renal disease (ESRD).  The successful completion of the feasibility study could set the stage for a pivotal efficacy study necessary to obtain potential market clearance to treat cardiovascular disease. 

While the therapeutic benefit of lipoprotein apheresis has been well established, treatment access is limited to fewer than 60 specialized apheresis centers in the United States. Whereas Sigyn Therapy™ is designed for use on dialysis machines already located in approximately 7,500 U.S. dialysis clinics.  

To learn more about Dr. Zaba, please click on the following link.

https://www.sigyntherapeutics.com/about/scientific-advisory-board

About Sigyn Therapeutics™

Sigyn Therapeutics is developing dialysis-like therapies to address cardiovascular disease and cancer. Sigyn Therapy™ is a first-in-class whole blood adsorption technology being advanced to treat cardiovascular disease, the leading cause of global deaths.  The technology is designed to reduce the circulating presence of inflammatory molecules that drive cardiovascular disease progression while simultaneously targeting cholesterol transporting lipoproteins that contribute to heart attacks, strokes, and other major adverse cardiovascular events. The extracorporeal removal of lipoprotein(a) [Lp(a)] and low-density lipoprotein cholesterol [LDL-C] from the bloodstream (commercially known as lipoprotein apheresis) is clinically reported to reduce the incidence of major adverse cardiovascular events by 55% to 98%.

Sigyn Therapeutics is also developing dialysis-like cancer therapies comprised of ImmunePrep(TM) to optimize the delivery of immunotherapeutic antibodies; ChemoPrep(TM) to enhance the targeted delivery of chemotherapy; and ChemoPure(TM) to reduce chemotherapy toxicity.  The Company plans to advance its cancer treatment candidates through joint venture development relationships. 

To learn more about Sigyn Therapeutics, visit: www.SigynTherapeutics.com 

CONTACT:
Sigyn Therapeutics, Inc.
Jim Joyce
CEO, Inventor
Email: jj@SigynTherapeutics.com

Cautionary Note Regarding Forward-Looking Statements

This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this summary are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Sigyn's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences may include, without limitation, the Company's ability to clinically advance Sigyn Therapy in human studies required for market clearance, the Company's ability to manufacture Sigyn Therapy, the Company's ability to raise capital resources, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this report speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

 

 

View the original release on www.newmediawire.com

More News

View More
Nike’s Turnaround: If the Shoe Fits, Buy It!
Via MarketBeat
Tickers NKE
NVIDIA Breaks Out to New Highs: What Comes Next?
Via MarketBeat
Topics Economy Stocks World Trade
Tickers CRWV META NVDA
Microsoft Stock Hits Stride in 2025—How Much More Can It Run?
Via MarketBeat
Topics Artificial Intelligence Retirement
Tickers MSFT
How Berkshire's OxyChem Buy Cements Its Long-Term Strength
Via MarketBeat
Tickers BRK BRK-A BRK-B OXY
Oklo Insiders Sell! Oh No! This Is Why Investors Shouldn’t Worry
Via MarketBeat
Tickers OKLO
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.